These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 35576991)

  • 1. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
    Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
    Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
    Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
    Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
    Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model.
    Hawley LE; Stringer M; Deal AJ; Folz A; Goodlett CR; Roper RJ
    Neurobiol Dis; 2024 Jan; 190():106359. PubMed ID: 37992782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
    Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
    Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
    Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
    J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model.
    LaCombe JM; Sloan K; Thomas JR; Blackwell MP; Crawford I; Bishop F; Wallace JM; Roper RJ
    Dis Model Mech; 2024 Sep; 17(9):. PubMed ID: 39136051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
    Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
    Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
    Blazek JD; Abeysekera I; Li J; Roper RJ
    Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
    McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
    Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.
    Stringer M; Goodlett CR; Roper RJ
    Mol Genet Genomic Med; 2017 Sep; 5(5):451-465. PubMed ID: 28944229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.
    Hijazi M; Medina JM; Velasco A
    Mol Neurobiol; 2017 Mar; 54(2):1092-1100. PubMed ID: 26803494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
    Hijazi M; Fillat C; Medina JM; Velasco A
    Exp Neurol; 2013 Jan; 239():229-34. PubMed ID: 23124096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
    De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
    Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Mmu17 Non-Hsa21 Orthologous Genes in the Ts65Dn Mouse Model of Down Syndrome: The Gold Standard Refuted.
    Guedj F; Kane E; Bishop LA; Pennings JLA; Herault Y; Bianchi DW
    Biol Psychiatry; 2023 Jul; 94(1):84-97. PubMed ID: 37074246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex specific emergence of trisomic
    LaCombe JM; Sloan K; Thomas JR; Blackwell MP; Crawford I; Wallace JM; Roper RJ
    bioRxiv; 2024 May; ():. PubMed ID: 38826419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
    García-Cerro S; Martínez P; Vidal V; Corrales A; Flórez J; Vidal R; Rueda N; Arbonés ML; Martínez-Cué C
    PLoS One; 2014; 9(9):e106572. PubMed ID: 25188425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.